Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Australia Down-Classifies Certain IVDs, Gives Labs New Conformity Assessment Option

This article was originally published in SRA

Executive Summary

New rules in Australia have resulted in the down-classification of a small number of IVDs intended to detect certain pathogens and the introduction of an alternative conformity assessment procedure for laboratories that manufacture Class 4 in-house IVDs1.

You may also be interested in...



New Filings At The EMA

New medicines under evaluation at the European Medicines Agency.

EU: Pfizer Warns Doctors About Blood Clot Risk With Xeljanz

Now that the European Medicines Agency has finalized its formal safety review procedure into Xeljanz, Pfizer is telling health care professionals what precautions they must take when prescribing the drug.

Win For Axonics As England’s NICE Says Rechargeable Neuromodulation Is Cost-Effective

Health technology assessment body NICE is consulting on draft guidance that recommends Axonics' device for overactive bladder.

UsernamePublicRestriction

Register

MT040660

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel